$-1.62 EPS Expected for Agios Pharmaceuticals, Inc. (AGIO)

July 14, 2018 - By Pearl Odom

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment increased to 1.72 in Q1 2018. Its up 0.50, from 1.22 in 2017Q4. It improved, as 13 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.93 million shares or 15.82% more from 45.70 million shares in 2017Q4 were reported.
Tarbox Family Office has 16 shares for 0% of their portfolio. Vanguard Group accumulated 4.00 million shares. First Allied Advisory Services has invested 0.04% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Lord Abbett & Limited Co stated it has 0.25% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Mitsubishi Ufj Trust And reported 0.04% stake. Platinum stated it has 0.07% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). North Star Asset Mgmt reported 5,600 shares. Renaissance Technologies Ltd Co accumulated 69,100 shares. Metropolitan Life Ins stated it has 3,519 shares. 130,000 are held by Opaleye Mgmt. Us Bank & Trust De owns 113 shares. Blackrock reported 3.21 million shares stake. Hood River has invested 0.61% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Advisory Services Networks Ltd Liability Com reported 80 shares or 0% of all its holdings. Capital Guardian Trust Company reported 0.76% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Since January 16, 2018, it had 1 insider purchase, and 32 selling transactions for $31.33 million activity. Biller Scott had sold 3,000 shares worth $280,101 on Tuesday, June 5. $157,500 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Bowden Christopher on Thursday, February 1. $175,808 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were sold by Hoerter Steven L.. $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was bought by Scadden David. Foster-Cheek Kaye I sold $841,926 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, June 14. The insider Alenson Carman sold $23,104.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.62 EPS on August, 14.They anticipate $0.16 EPS change or 8.99 % from last quarter’s $-1.78 EPS. After having $-1.63 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see -0.61 % EPS growth. The stock decreased 0.09% or $0.08 during the last trading session, reaching $90.4. About 158,829 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 88.28% since July 14, 2017 and is uptrending. It has outperformed by 75.71% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 7 analysts covering Agios Pharma (NASDAQ:AGIO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Agios Pharma had 8 analyst reports since February 14, 2018 according to SRatingsIntel. The rating was initiated by Piper Jaffray with “Buy” on Wednesday, May 30. The rating was initiated by Oppenheimer on Monday, June 18 with “Hold”. The company was maintained on Wednesday, February 14 by RBC Capital Markets. The firm has “Buy” rating by Credit Suisse given on Thursday, February 15. JP Morgan maintained the shares of AGIO in report on Thursday, February 15 with “Overweight” rating. Credit Suisse maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Wednesday, April 11 with “Outperform” rating.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.21 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals …” on June 29, 2018, also Seekingalpha.com with their article: “Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal” published on July 01, 2018, Nasdaq.com published: “Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency …” on June 18, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018 as well as Nasdaq.com‘s news article titled: “Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and …” with publication date: June 26, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.